Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls

1 Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK 2 Geriatric Medicine Unit, University of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh EH16 4SB,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medical microbiology 2008-06, Vol.57 (6), p.717-724
Hauptverfasser: Sanchez-Hurtado, Karla, Corretge, Maria, Mutlu, Esvet, McIlhagger, Rowan, Starr, John M, Poxton, Ian R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 724
container_issue 6
container_start_page 717
container_title Journal of medical microbiology
container_volume 57
creator Sanchez-Hurtado, Karla
Corretge, Maria
Mutlu, Esvet
McIlhagger, Rowan
Starr, John M
Poxton, Ian R
description 1 Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK 2 Geriatric Medicine Unit, University of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh EH16 4SB, UK Correspondence Ian R. Poxton i.r.poxton{at}ed.ac.uk Received 23 October 2007 Accepted 30 January 2008 It has been proposed that patients who develop Clostridium difficile -associated disease (CDAD) do so because they are unable to mount an adequate immune response. Serum was collected from three groups of elderly in-patients: (i) cases ( n =21) of CDAD, being toxin A/B-positive; (ii) carriers ( n =21) asymptomatic for CDAD (no diarrhoea) but at least toxin or culture positive; and (iii) controls ( n =26) asymptomatic for CDAD and negative for both C. difficile toxin and culture. The age and gender of each group were compared, and the colonizing strains were ribotyped and toxinotyped. Serum antibodies (IgG and IgM) were measured by ELISA using different antigen preparations: EDTA extract (containing cell-surface proteins and carbohydrates), guanidine hydrochloride extract (surface-layer proteins), aqueous phenol-extracted lipocarbohydrate (LC); crude toxin (dialysis culture supernatant) and purified toxin A. LPS from Escherichia coli was used as a control antigen. Antibodies were also tested for toxin neutralization on tissue monolayers and for binding to EDTA-extracted antigens by Western blotting. IgG antibody measurements to cytomegalovirus (CMV) were included as an indicator of potential immunosenescence. Results showed that the patient groups were well matched by age and gender, and the colonizing strains were similar in cases and carriers, being predominantly ribotype 001 and toxinotype 0. By ELISA, IgG levels to most of the antigens were highest in the cases and lowest in the controls, with the exception of antibodies to the LC, which were higher in the controls than the cases. Levels in the carriers tended to be of intermediate level or similar to the controls. For all antigens, the levels of IgM were not significantly different among cases, carriers and controls. Serum from all groups was able to neutralize the cytotoxic action of toxin on both Vero and Caco2 cells, and all to a similar extent. Western blots showed an overall higher level of IgG antibodies to the EDTA-extracted antigens in the cases. The results of the CMV ELISA showed that specific IgG w
doi_str_mv 10.1099/jmm.0.47713-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70733727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70733727</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-926e560ab5ca51906c80a006271eaa39b71f9b1099994bb718195242efdd04013</originalsourceid><addsrcrecordid>eNqFkUtr3DAURkVpaaZJl90WrZqVJ1cPW9YyDElaCHSRZi1kWc4oWJYryaSTXx_NA7Ls6j44fFzuQegbgTUBKa-evV_DmgtBWAUf0Ipwwaq64fwjWgFQWtGG1GfoS0rPAEQwJj-jM9LyFhhtV-jfwy5l653BesquC_0OR5vmMCWLc8CbMaQcXe8Wj3s3DM640WI3YRPGMLlX2-NZZ2ennPCLy9uS0h-asGScdn7OwafD0utstgU3YcoxjOkCfRr0mOzXUz1Hj7c3fzY_q_vfd7821_eVYZLlStLG1g3orja6JhIa04IGaKggVmsmO0EG2e0_ISXvytQSWVNO7dD3wIGwc_TjmDvH8HexKSvvkrHjqCcblqQElJ8IKv4LUmibVvC2gNURNDGkFO2g5ui8jjtFQO0vUcWJAnVwoqDw30_BS-dt_06fJBTg8ghs3dP2xUWrnuxUlMTQubAPq4VqlCjy3gBZ3ZeX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20868748</pqid></control><display><type>article</type><title>Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls</title><source>MEDLINE</source><source>Microbiology Society</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sanchez-Hurtado, Karla ; Corretge, Maria ; Mutlu, Esvet ; McIlhagger, Rowan ; Starr, John M ; Poxton, Ian R</creator><creatorcontrib>Sanchez-Hurtado, Karla ; Corretge, Maria ; Mutlu, Esvet ; McIlhagger, Rowan ; Starr, John M ; Poxton, Ian R</creatorcontrib><description>1 Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK 2 Geriatric Medicine Unit, University of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh EH16 4SB, UK Correspondence Ian R. Poxton i.r.poxton{at}ed.ac.uk Received 23 October 2007 Accepted 30 January 2008 It has been proposed that patients who develop Clostridium difficile -associated disease (CDAD) do so because they are unable to mount an adequate immune response. Serum was collected from three groups of elderly in-patients: (i) cases ( n =21) of CDAD, being toxin A/B-positive; (ii) carriers ( n =21) asymptomatic for CDAD (no diarrhoea) but at least toxin or culture positive; and (iii) controls ( n =26) asymptomatic for CDAD and negative for both C. difficile toxin and culture. The age and gender of each group were compared, and the colonizing strains were ribotyped and toxinotyped. Serum antibodies (IgG and IgM) were measured by ELISA using different antigen preparations: EDTA extract (containing cell-surface proteins and carbohydrates), guanidine hydrochloride extract (surface-layer proteins), aqueous phenol-extracted lipocarbohydrate (LC); crude toxin (dialysis culture supernatant) and purified toxin A. LPS from Escherichia coli was used as a control antigen. Antibodies were also tested for toxin neutralization on tissue monolayers and for binding to EDTA-extracted antigens by Western blotting. IgG antibody measurements to cytomegalovirus (CMV) were included as an indicator of potential immunosenescence. Results showed that the patient groups were well matched by age and gender, and the colonizing strains were similar in cases and carriers, being predominantly ribotype 001 and toxinotype 0. By ELISA, IgG levels to most of the antigens were highest in the cases and lowest in the controls, with the exception of antibodies to the LC, which were higher in the controls than the cases. Levels in the carriers tended to be of intermediate level or similar to the controls. For all antigens, the levels of IgM were not significantly different among cases, carriers and controls. Serum from all groups was able to neutralize the cytotoxic action of toxin on both Vero and Caco2 cells, and all to a similar extent. Western blots showed an overall higher level of IgG antibodies to the EDTA-extracted antigens in the cases. The results of the CMV ELISA showed that specific IgG was detected in more cases (78 %) than carriers and controls (both 65 %), but this difference in seropositivity was not significant. The conclusion is that, during symptomatic infection, patients respond to protein antigens of C. difficile in a manner typical of a secondary antibody response, with no evidence that an inability to respond predisposes to the appearance of symptoms. Abbreviations: AP, alkaline phosphatase; CDAD, Clostridium difficile -associated disease; CMV, cytomegalovirus; LC, lipocarbohydrate; SLP, surface-layer protein.</description><identifier>ISSN: 0022-2615</identifier><identifier>EISSN: 1473-5644</identifier><identifier>DOI: 10.1099/jmm.0.47713-0</identifier><identifier>PMID: 18480328</identifier><language>eng</language><publisher>England: Soc General Microbiol</publisher><subject>Aged ; Aged, 80 and over ; Animals ; Antibodies, Bacterial - biosynthesis ; Antibodies, Bacterial - blood ; Antibodies, Viral - blood ; Antigens, Bacterial - immunology ; Bacterial Toxins - immunology ; Caco-2 Cells ; Carrier State - immunology ; Case-Control Studies ; Chlorocebus aethiops ; Clostridium ; Clostridium difficile ; Clostridium difficile - immunology ; Clostridium Infections - complications ; Clostridium Infections - immunology ; Cytomegalovirus ; Cytomegalovirus - immunology ; Cytomegalovirus Infections - complications ; Cytomegalovirus Infections - immunology ; Escherichia coli ; Feces - microbiology ; Female ; Humans ; Immunoglobulin G - biosynthesis ; Immunoglobulin G - blood ; Immunoglobulin M - biosynthesis ; Immunoglobulin M - blood ; Male ; Vero Cells</subject><ispartof>Journal of medical microbiology, 2008-06, Vol.57 (6), p.717-724</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-926e560ab5ca51906c80a006271eaa39b71f9b1099994bb718195242efdd04013</citedby><cites>FETCH-LOGICAL-c393t-926e560ab5ca51906c80a006271eaa39b71f9b1099994bb718195242efdd04013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3746,3747,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18480328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchez-Hurtado, Karla</creatorcontrib><creatorcontrib>Corretge, Maria</creatorcontrib><creatorcontrib>Mutlu, Esvet</creatorcontrib><creatorcontrib>McIlhagger, Rowan</creatorcontrib><creatorcontrib>Starr, John M</creatorcontrib><creatorcontrib>Poxton, Ian R</creatorcontrib><title>Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls</title><title>Journal of medical microbiology</title><addtitle>J Med Microbiol</addtitle><description>1 Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK 2 Geriatric Medicine Unit, University of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh EH16 4SB, UK Correspondence Ian R. Poxton i.r.poxton{at}ed.ac.uk Received 23 October 2007 Accepted 30 January 2008 It has been proposed that patients who develop Clostridium difficile -associated disease (CDAD) do so because they are unable to mount an adequate immune response. Serum was collected from three groups of elderly in-patients: (i) cases ( n =21) of CDAD, being toxin A/B-positive; (ii) carriers ( n =21) asymptomatic for CDAD (no diarrhoea) but at least toxin or culture positive; and (iii) controls ( n =26) asymptomatic for CDAD and negative for both C. difficile toxin and culture. The age and gender of each group were compared, and the colonizing strains were ribotyped and toxinotyped. Serum antibodies (IgG and IgM) were measured by ELISA using different antigen preparations: EDTA extract (containing cell-surface proteins and carbohydrates), guanidine hydrochloride extract (surface-layer proteins), aqueous phenol-extracted lipocarbohydrate (LC); crude toxin (dialysis culture supernatant) and purified toxin A. LPS from Escherichia coli was used as a control antigen. Antibodies were also tested for toxin neutralization on tissue monolayers and for binding to EDTA-extracted antigens by Western blotting. IgG antibody measurements to cytomegalovirus (CMV) were included as an indicator of potential immunosenescence. Results showed that the patient groups were well matched by age and gender, and the colonizing strains were similar in cases and carriers, being predominantly ribotype 001 and toxinotype 0. By ELISA, IgG levels to most of the antigens were highest in the cases and lowest in the controls, with the exception of antibodies to the LC, which were higher in the controls than the cases. Levels in the carriers tended to be of intermediate level or similar to the controls. For all antigens, the levels of IgM were not significantly different among cases, carriers and controls. Serum from all groups was able to neutralize the cytotoxic action of toxin on both Vero and Caco2 cells, and all to a similar extent. Western blots showed an overall higher level of IgG antibodies to the EDTA-extracted antigens in the cases. The results of the CMV ELISA showed that specific IgG was detected in more cases (78 %) than carriers and controls (both 65 %), but this difference in seropositivity was not significant. The conclusion is that, during symptomatic infection, patients respond to protein antigens of C. difficile in a manner typical of a secondary antibody response, with no evidence that an inability to respond predisposes to the appearance of symptoms. Abbreviations: AP, alkaline phosphatase; CDAD, Clostridium difficile -associated disease; CMV, cytomegalovirus; LC, lipocarbohydrate; SLP, surface-layer protein.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Antibodies, Bacterial - biosynthesis</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens, Bacterial - immunology</subject><subject>Bacterial Toxins - immunology</subject><subject>Caco-2 Cells</subject><subject>Carrier State - immunology</subject><subject>Case-Control Studies</subject><subject>Chlorocebus aethiops</subject><subject>Clostridium</subject><subject>Clostridium difficile</subject><subject>Clostridium difficile - immunology</subject><subject>Clostridium Infections - complications</subject><subject>Clostridium Infections - immunology</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus - immunology</subject><subject>Cytomegalovirus Infections - complications</subject><subject>Cytomegalovirus Infections - immunology</subject><subject>Escherichia coli</subject><subject>Feces - microbiology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - biosynthesis</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin M - biosynthesis</subject><subject>Immunoglobulin M - blood</subject><subject>Male</subject><subject>Vero Cells</subject><issn>0022-2615</issn><issn>1473-5644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtr3DAURkVpaaZJl90WrZqVJ1cPW9YyDElaCHSRZi1kWc4oWJYryaSTXx_NA7Ls6j44fFzuQegbgTUBKa-evV_DmgtBWAUf0Ipwwaq64fwjWgFQWtGG1GfoS0rPAEQwJj-jM9LyFhhtV-jfwy5l653BesquC_0OR5vmMCWLc8CbMaQcXe8Wj3s3DM640WI3YRPGMLlX2-NZZ2ennPCLy9uS0h-asGScdn7OwafD0utstgU3YcoxjOkCfRr0mOzXUz1Hj7c3fzY_q_vfd7821_eVYZLlStLG1g3orja6JhIa04IGaKggVmsmO0EG2e0_ISXvytQSWVNO7dD3wIGwc_TjmDvH8HexKSvvkrHjqCcblqQElJ8IKv4LUmibVvC2gNURNDGkFO2g5ui8jjtFQO0vUcWJAnVwoqDw30_BS-dt_06fJBTg8ghs3dP2xUWrnuxUlMTQubAPq4VqlCjy3gBZ3ZeX</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Sanchez-Hurtado, Karla</creator><creator>Corretge, Maria</creator><creator>Mutlu, Esvet</creator><creator>McIlhagger, Rowan</creator><creator>Starr, John M</creator><creator>Poxton, Ian R</creator><general>Soc General Microbiol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20080601</creationdate><title>Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls</title><author>Sanchez-Hurtado, Karla ; Corretge, Maria ; Mutlu, Esvet ; McIlhagger, Rowan ; Starr, John M ; Poxton, Ian R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-926e560ab5ca51906c80a006271eaa39b71f9b1099994bb718195242efdd04013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Antibodies, Bacterial - biosynthesis</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens, Bacterial - immunology</topic><topic>Bacterial Toxins - immunology</topic><topic>Caco-2 Cells</topic><topic>Carrier State - immunology</topic><topic>Case-Control Studies</topic><topic>Chlorocebus aethiops</topic><topic>Clostridium</topic><topic>Clostridium difficile</topic><topic>Clostridium difficile - immunology</topic><topic>Clostridium Infections - complications</topic><topic>Clostridium Infections - immunology</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus - immunology</topic><topic>Cytomegalovirus Infections - complications</topic><topic>Cytomegalovirus Infections - immunology</topic><topic>Escherichia coli</topic><topic>Feces - microbiology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - biosynthesis</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin M - biosynthesis</topic><topic>Immunoglobulin M - blood</topic><topic>Male</topic><topic>Vero Cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez-Hurtado, Karla</creatorcontrib><creatorcontrib>Corretge, Maria</creatorcontrib><creatorcontrib>Mutlu, Esvet</creatorcontrib><creatorcontrib>McIlhagger, Rowan</creatorcontrib><creatorcontrib>Starr, John M</creatorcontrib><creatorcontrib>Poxton, Ian R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez-Hurtado, Karla</au><au>Corretge, Maria</au><au>Mutlu, Esvet</au><au>McIlhagger, Rowan</au><au>Starr, John M</au><au>Poxton, Ian R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls</atitle><jtitle>Journal of medical microbiology</jtitle><addtitle>J Med Microbiol</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>57</volume><issue>6</issue><spage>717</spage><epage>724</epage><pages>717-724</pages><issn>0022-2615</issn><eissn>1473-5644</eissn><abstract>1 Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK 2 Geriatric Medicine Unit, University of Edinburgh College of Medicine and Veterinary Medicine, Edinburgh EH16 4SB, UK Correspondence Ian R. Poxton i.r.poxton{at}ed.ac.uk Received 23 October 2007 Accepted 30 January 2008 It has been proposed that patients who develop Clostridium difficile -associated disease (CDAD) do so because they are unable to mount an adequate immune response. Serum was collected from three groups of elderly in-patients: (i) cases ( n =21) of CDAD, being toxin A/B-positive; (ii) carriers ( n =21) asymptomatic for CDAD (no diarrhoea) but at least toxin or culture positive; and (iii) controls ( n =26) asymptomatic for CDAD and negative for both C. difficile toxin and culture. The age and gender of each group were compared, and the colonizing strains were ribotyped and toxinotyped. Serum antibodies (IgG and IgM) were measured by ELISA using different antigen preparations: EDTA extract (containing cell-surface proteins and carbohydrates), guanidine hydrochloride extract (surface-layer proteins), aqueous phenol-extracted lipocarbohydrate (LC); crude toxin (dialysis culture supernatant) and purified toxin A. LPS from Escherichia coli was used as a control antigen. Antibodies were also tested for toxin neutralization on tissue monolayers and for binding to EDTA-extracted antigens by Western blotting. IgG antibody measurements to cytomegalovirus (CMV) were included as an indicator of potential immunosenescence. Results showed that the patient groups were well matched by age and gender, and the colonizing strains were similar in cases and carriers, being predominantly ribotype 001 and toxinotype 0. By ELISA, IgG levels to most of the antigens were highest in the cases and lowest in the controls, with the exception of antibodies to the LC, which were higher in the controls than the cases. Levels in the carriers tended to be of intermediate level or similar to the controls. For all antigens, the levels of IgM were not significantly different among cases, carriers and controls. Serum from all groups was able to neutralize the cytotoxic action of toxin on both Vero and Caco2 cells, and all to a similar extent. Western blots showed an overall higher level of IgG antibodies to the EDTA-extracted antigens in the cases. The results of the CMV ELISA showed that specific IgG was detected in more cases (78 %) than carriers and controls (both 65 %), but this difference in seropositivity was not significant. The conclusion is that, during symptomatic infection, patients respond to protein antigens of C. difficile in a manner typical of a secondary antibody response, with no evidence that an inability to respond predisposes to the appearance of symptoms. Abbreviations: AP, alkaline phosphatase; CDAD, Clostridium difficile -associated disease; CMV, cytomegalovirus; LC, lipocarbohydrate; SLP, surface-layer protein.</abstract><cop>England</cop><pub>Soc General Microbiol</pub><pmid>18480328</pmid><doi>10.1099/jmm.0.47713-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2615
ispartof Journal of medical microbiology, 2008-06, Vol.57 (6), p.717-724
issn 0022-2615
1473-5644
language eng
recordid cdi_proquest_miscellaneous_70733727
source MEDLINE; Microbiology Society; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Aged
Aged, 80 and over
Animals
Antibodies, Bacterial - biosynthesis
Antibodies, Bacterial - blood
Antibodies, Viral - blood
Antigens, Bacterial - immunology
Bacterial Toxins - immunology
Caco-2 Cells
Carrier State - immunology
Case-Control Studies
Chlorocebus aethiops
Clostridium
Clostridium difficile
Clostridium difficile - immunology
Clostridium Infections - complications
Clostridium Infections - immunology
Cytomegalovirus
Cytomegalovirus - immunology
Cytomegalovirus Infections - complications
Cytomegalovirus Infections - immunology
Escherichia coli
Feces - microbiology
Female
Humans
Immunoglobulin G - biosynthesis
Immunoglobulin G - blood
Immunoglobulin M - biosynthesis
Immunoglobulin M - blood
Male
Vero Cells
title Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A43%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20antibody%20response%20to%20Clostridium%20difficile%20in%20colonized%20patients%20with%20and%20without%20symptoms%20and%20matched%20controls&rft.jtitle=Journal%20of%20medical%20microbiology&rft.au=Sanchez-Hurtado,%20Karla&rft.date=2008-06-01&rft.volume=57&rft.issue=6&rft.spage=717&rft.epage=724&rft.pages=717-724&rft.issn=0022-2615&rft.eissn=1473-5644&rft_id=info:doi/10.1099/jmm.0.47713-0&rft_dat=%3Cproquest_cross%3E70733727%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20868748&rft_id=info:pmid/18480328&rfr_iscdi=true